HK Stock MarketDetailed Quotes
00853 MICROPORT
- 5.110
- +0.510+11.09%
Market Closed Sep 13 16:08 CST
9.38BMarket Cap-2915P/E (TTM)
5.150High4.600Low19.79MVolume4.600Open4.600Pre Close98.40MTurnover1.08%Turnover RatioLossP/E (Static)1.83BShares14.24052wk High1.72P/B9.38BFloat Cap4.46052wk Low--Dividend TTM1.83BShs Float72.850Historical High--Dividend LFY11.96%Amplitude2.461Historical Low4.972Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data
MICROPORT Stock Forum
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
$MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $CSPC PHARMA (01093.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
$BEIGENE (06160.HK)$ $CSPC PHARMA (01093.HK)$ $HENLIUS (02696.HK)$ $MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
The launch of robots has not boosted the market value of minimally invasive medicine at all. Very disappointed. This was out of the blue. The medical and instrument sector has been cold recently. There was no interest from listed institutional investors. Equity issues are rare. The offering is worth just over $25 billion in Series C financing. Reflect on this increase did not achieve the desired purpose.
Minimally Invasive has acquired Hemovent inc., a 2013 Aachen based medical device company specializing in innovative in vitro life support systems, for an aggregate price of up to €123 million. The company's main product is ECMO, and its MOBYBOX System, which is the world's first ECMO System integrating blood pump and membrane lung, has received CE certification.
No comment yet